The 2026 ASLS, held for two days from April 11 to 12 at COEX Magok in Seoul, has successfully concluded. CHAMEDITECH participated with a Platinum booth and newly showcased the HYRAURA SKINBOOSTER, which was launched last March.
The HYRAURA SKINBOOSTER is a skin booster designed with the characteristics of the dWAT layer (Dermal White Adipose Tissue), which is located between the dermis and subcutaneous fat and plays a role in supporting the skin.
This event marks the first time the HYRAURA SKINBOOSTER, which has demonstrated significant effectiveness in actual clinical procedures regarding wrinkles, redness/pigmentation, pores, and skin tone, has been presented at an aesthetic academic conference. The CHAMEDITECH booth consisted of a consultation zone and a photo zone, attracting a diverse range of domestic and international visitors who took photos after consulting about products, including the HYRAURA SKINBOOSTER.
In addition, surprise events were held once in the morning and once in the afternoon. The surprise event, which offered cosmetics containing ingredients exclusively developed by CHAMEDITECH such as CELLTERMI Itch Relief Cream and REPAIR SOOTHING Mask, concluded with great success due to the interest of visitors even before it began.
Over the course of two days, this ASLS featured four lectures by three speakers: Dr. Jeongwoo Lee (Elev Clinic), Dr. Hyesun Park (Elev Clinic), and Dr. Kanghoon Choi (Obliv Clinic). The lectures provided an in-depth introduction to the unique techniques of HYRAURA SKINBOOSTER and its 2mm vertical injection method, approaching the actual effects of HYRAURA SKINBOOSTER from a clinical perspective. Through this, the event demonstrated the potential for HYRAURA SKINBOOSTER to emerge as the new mainstream HA skin booster.
An official of CHAMEDITECH said, "Based on the positive response from medical professionals observed at this event, CHAMEDITECH will strengthen its marketing efforts and strive to establish HYRAURA SKINBOOSTER as the new standard for next-generation skin boosters".